Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. More Details
6 star dividend payer with solid track record.
Share Price & News
How has Sinopharm Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: X2S1 is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: Insufficient data to determine X2S1's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how X2S1 performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how X2S1 performed against the German Market.
Long-Term Price Volatility Vs. Market
How volatile is Sinopharm Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: X2S1 (€10.68) is trading above our estimate of fair value (€5.95)
Significantly Below Fair Value: X2S1 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: X2S1 is good value based on its PE Ratio (7.9x) compared to the DE Healthcare industry average (32.5x).
PE vs Market: X2S1 is good value based on its PE Ratio (7.9x) compared to the German market (28.2x).
Price to Earnings Growth Ratio
PEG Ratio: X2S1 is poor value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: X2S1 is good value based on its PB Ratio (0.9x) compared to the DE Healthcare industry average (1.7x).
How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: X2S1's forecast earnings growth (7.9% per year) is above the savings rate (0.07%).
Earnings vs Market: X2S1's earnings (7.9% per year) are forecast to grow slower than the German market (20.9% per year).
High Growth Earnings: X2S1's earnings are forecast to grow, but not significantly.
Revenue vs Market: X2S1's revenue (9% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: X2S1's revenue (9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: X2S1's Return on Equity is forecast to be low in 3 years time (12.8%).
How has Sinopharm Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: X2S1 has high quality earnings.
Growing Profit Margin: X2S1's current net profit margins (1.6%) are higher than last year (1.5%).
Past Earnings Growth Analysis
Earnings Trend: X2S1's earnings have grown by 10.6% per year over the past 5 years.
Accelerating Growth: X2S1's earnings growth over the past year (14.9%) exceeds its 5-year average (10.6% per year).
Earnings vs Industry: X2S1 earnings growth over the past year (14.9%) exceeded the Healthcare industry 2%.
Return on Equity
High ROE: X2S1's Return on Equity (13.4%) is considered low.
How is Sinopharm Group's financial position?
Financial Position Analysis
Short Term Liabilities: X2S1's short term assets (CN¥267.6B) exceed its short term liabilities (CN¥204.0B).
Long Term Liabilities: X2S1's short term assets (CN¥267.6B) exceed its long term liabilities (CN¥17.3B).
Debt to Equity History and Analysis
Debt Level: X2S1's debt to equity ratio (71%) is considered high.
Reducing Debt: X2S1's debt to equity ratio has increased from 70.9% to 71% over the past 5 years.
Debt Coverage: X2S1's debt is not well covered by operating cash flow (17.5%).
Interest Coverage: X2S1's interest payments on its debt are well covered by EBIT (5.5x coverage).
What is Sinopharm Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: X2S1's dividend (3.43%) is higher than the bottom 25% of dividend payers in the German market (1.06%).
High Dividend: X2S1's dividend (3.43%) is in the top 25% of dividend payers in the German market (3.21%)
Stability and Growth of Payments
Stable Dividend: X2S1's dividends per share have been stable in the past 10 years.
Growing Dividend: X2S1's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27.1%), X2S1's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: X2S1's dividends in 3 years are forecast to be well covered by earnings (25.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yong Liu (51 yo)
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...
CEO Compensation Analysis
Compensation vs Market: Yong's total compensation ($USD1.14M) is below average for companies of similar size in the German market ($USD3.26M).
Compensation vs Earnings: Yong's compensation has been consistent with company performance over the past year.
Experienced Management: X2S1's management team is considered experienced (3.4 years average tenure).
Experienced Board: X2S1's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sinopharm Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Sinopharm Group Co., Ltd.
- Ticker: X2S1
- Exchange: DB
- Founded: 2003
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: HK$64.670b
- Listing Market Cap: HK$6.954b
- Shares outstanding: 3.12b
- Website: https://www.sinopharmgroup.com.cn
Number of Employees
- Sinopharm Group Co., Ltd.
- Sinopharm Plaza
- No. 1001 Zhongshan Road (West)
- Shanghai Province
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. Its Pharmaceutical Distribution se...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/14 19:46|
|End of Day Share Price||2021/04/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.